The latest update is out from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ).
KPC Pharmaceuticals, a subsidiary of China Resources Pharmaceutical Group Ltd., reported its financial results for the year ending December 31, 2024. The company experienced a slight decrease in revenue by 0.34% but saw a significant increase in net profit attributable to shareholders by 19.86%. The board proposed a cash dividend of RMB3.00 per 10 shares, pending approval at the annual general meeting. The financial results highlight KPC’s operational resilience and potential positive impact on shareholder returns, despite a decrease in net assets attributable to shareholders.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. is involved in the pharmaceutical industry, focusing on medical and pharmaceutical products. It holds a significant equity interest in KPC Pharmaceuticals, a company listed on the Shanghai Stock Exchange.
YTD Price Performance: -9.56%
Average Trading Volume: 1,702
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €3.9B
See more insights into 3320 stock on TipRanks’ Stock Analysis page.